Merck Insomnia Drug Safe Only in Low Doses

May 23 (Bloomberg) -- Merck & Co.’s experimental insomnia drug, meant to be a less disruptive alternative to Sanofi’s Ambien sleeping pill, is safe only at lower doses, U.S. regulatory advisers said. Olivia Sterns reports on Bloomberg Television's "Bottom Line." (Source: Bloomberg)

BOJ Policy: How Will the Decision Impact the Yen?
59:49 - Shusuke Yamada, chief Japan FX strategist at Bank of America Merrill Lynch, discusses the Bank of Japan's policy decision, how it will impact the yen and the possibility of helicopter money entering the market. He speaks to Bloomberg's Yvonne Man on "Daybreak Asia." (Source: Bloomberg)
  • Yen Volatility Weighs on Japan Inc.
  • Assessing Hong Kong and China Housing Markets
  • Baidu's Forecast Misses Estimates on New Ad Rules